Anticipated $-0.07 EPS for IntelliPharmaCeutics International Inc. (IPCI) on July, 10

June 27, 2018 - By Jeanette Garcia

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Corporate Logo

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI)’s earnings report is anticipated on July, 10., as reported by Faxor. This year’s EPS analyst estimate is anticipated to be $-0.07. That is 16.67 % down compareed to $-0.06 EPS for last year. -22.22 % EPS growth is what Wall Street’s predicts after $-0.09 reported EPS last quarter. IPCI is hitting $0.4368 during the last trading session, after decreased 0.73%.IntelliPharmaCeutics International Inc. has volume of 18,268 shares. Since June 27, 2017 IPCI has declined 78.43% and is downtrending. IPCI underperformed by 91.00% the S&P 500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

A total of 2 analysts rate IntelliPharmaCeutics Intl (NASDAQ:IPCI) as follows: 1 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 50% are bullish. The firm has $2.5 highest and $2.5000 lowest target. The avg target $5.25 is 1101.92% above the last ($0.4368) price. (NASDAQ:IPCI) has 6 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Friday, February 16 the stock has “Hold” rating by Maxim Group. On Monday, March 5 the stock has “Buy” rating by H.C. Wainwright. The company rating was maintained by H.C. Wainwright on Monday, February 12. On Tuesday, May 29 the firm has “Buy” rating given by H.C. Wainwright.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada.The firm is worth $19.05 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.Last it reported negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

There’s a significant IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news released by It’s a report titled: “IntelliPharmaCeutics Intl (NASDAQ:IPCI) Earning Somewhat Critical Press Coverage, Accern Reports” on June 26, 2018.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.